Physician profile
Ryan Sears
NPI 1306162979
$5,303.15
in general payments reported to CMS, 2019-2025
40 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.62 · 2022: $760 · 2023: $1,088 · 2024: $1,773 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,509 · Education: $15.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,508.88 |
| Education | $15.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.43 | 2022-2025 | Ubrelvy, Qulipta, Synthroid |
| Lilly USA, LLC | $589.60 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $580.92 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $569.92 | 2022-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $335.59 | 2023-2025 | |
| Eisai INC. | $325.88 | 2024-2025 | |
| Novo Nordisk INC | $264.46 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $205.60 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.47 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $160.70 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $145.11 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $120.15 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.25 | 2022-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.86 | 2024-2025 | Caplyta |
| Amgen INC. | $95.96 | 2022-2025 | Otezla, Repatha, Otezla |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $84.35 | 2022-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $83.90 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $82.17 | 2024-2025 | Spravato, Xarelto |
| Astellas Pharma US INC | $62.45 | 2023-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $55.87 | 2022 | |
| Aimmune Therapeutics, INC. | $47.49 | 2024-2025 | Zenpep |
| Biogen, INC. | $37.36 | 2025 | Skyclarys |
| Teva Pharmaceuticals USA, INC. | $36.38 | 2022-2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $35.31 | 2025 | Voquezna |
| Corium, LLC | $34.42 | 2022-2023 | Azstarys |
| Krystal Biotech INC | $33.58 | 2024 | Vyjuvek |
| Impel Pharmaceuticals INC. | $32.75 | 2023 | Trudhesa |
| Alk-Abello, INC | $31.40 | 2023-2024 | Grastek, Odactra, Ragwitek |
| Upsher-Smith Laboratories LLC | $24.66 | 2022 | |
| Medtronic, INC. | $22.24 | 2024 | Intellis Adaptivestim |
| Pharmacosmos Therapeutics INC. | $20.39 | 2024 | Monoferric |
| Boston Scientific Corporation | $19.24 | 2024 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $18.62 | 2021 | |
| Sanofi Pasteur INC. | $18.51 | 2023 | |
| Dynavax Technologies Corporation | $18.27 | 2024 | Heplisav-B |
| Lundbeck LLC | $18.24 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $16.57 | 2023 | Belsomra |
| Dexcom, INC. | $16.15 | 2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $16.05 | 2025 | Inspire |
| Currax Pharmaceuticals LLC | $13.88 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.